DIFFICULTIES ANTIVIRAL THERAPY IN PATIENTS WITH HCV-CIRRHOSIS AND CHRONIC KIDNEY DISEASE

Download full text PDF
Issue: 
10
Year: 
2015

О. Lukina (1); А. Balashova (1); А. Almazova (2), Candidate of Medical Sciences; K. Evsigneeva (3); O. Arisheva (1,3), Candidate of Medical Sciences; I. Garmash (1), Candidate of Medical Sciences; O. Kotenko (1,3), Candidate of Medical Sciences 1 -Russian Peoples Friendship University, Moscow 2 -Hospital №64, Moscow 3 -Hospital №52, Moscow

Prior to the AVT chronic HCV-infection a careful assessment of comorbidity, especially renal function, so that's kidneys are involved in the metabolism of the majority of antiviral drugs, and can greatly influence the development of serious adverse events difficult to control, particularly anemia.
Keywords: 
antiviral therapy
anemia
chronic kidney disease

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Fried M., Shiffman M., Reddy K. et al. Peginterferon alfa-2a plus ribavirin of chronic hepatitis C virus infection // N. Engl. J. Med. – 2002; 347: 975–82.
  2. Pegasis2. ®. Instruktsija k meditsinskomu primeneniju.
  3. EASL. International Consensus Conference on Hepatitis C // J. Hepatol. – 3. 2002; (36): 973–7.
  4. Dieterich D., Wasserman R., Br4. äu N. et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa // Am. J. Gastroenterol. – 2003; 98: 2491–9.
  5. Brennan B., Wang K., Blotner S. et al. Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment // Antimicrob. Agents and Chemother. – 2013; 57 (12): 6097–105.
  6. Wang K., Lawal A., Majchrowitz M. et al. Pharmacokinetics (PK) of . ribavirin(RBV) in patients with renal impairment or end-stage disease (ESRD) and chronic hepatitis C during treatment with peginterferon alfa-2a (PEGASYS) and RBV(COPEGUS) // J. Hepatol. – 2008; 48: 1142.
  7. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection // J. Hepatol. – 2013; 60 (2): 392–420.
  8. Rebetol ®. Instruktsija po meditsinskomu primeneniju.
  9. Davis G., Wong J., McHutchison J. et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C // Hepatology. – 2003; 38: 645–52.
  10. Juschuk N.D., Ivashkin V.T., Zhdanov K.V. Rekomendatsii po diagnostike i lecheniju vzroslyh bol'nyh gepatitom S 2013 g. // Ros. zhurn. gastroenterol., gepatol., koloproktol. – 20134 23 (2): 41–70.
  11. Th11. évenot T., Cadranel J., Di Martino V. et al. A national French survey on the use of growth factors as adjuvant treatment of chronic hepatitis C // Hepatology. – 2007; 45: 377–83.
  12. Bakulin I.G. Sandler Ju.G. Gematologicheskie nezhelatel'nye javlenija pri provedenii protivovirusnoj terapii u bol'nyh s hronicheskim gepati-tom S // Gepatologicheskij forum. – 2011; 4: 2–14.
  13. Lindahl K., Schvarcz R., Bruchfeld A. et al. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anemia // J. Viral. Hepatol. – 2004; 11: 84–7.